Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting

Autor: Isacco Desideri, G. Tonini, Emanuela Magnolfi, L. Pizzuti, Jennifer Foglietta, Marina Elena Cazzaniga, Adamo, Patrizia Vici, Enrico Cortesi, Emanuela Risi, G. D'Auria, Loretta D'Onofrio, Mario Roselli, Isabella Sperduti, N. Tinari, Nicola D’Ostilio, A. Vaccaro, Icro Meattini, Federica Tomao, Giacomo Barchiesi, B Di Cocco, F Cardillo, Enzo Veltri, Claudia Omarini, Mirco Pistelli, Clara Natoli, Carlo Garufi, E. Landucci, M. Mauri, Rosanna Mirabelli, Federico Piacentini, Domenico Corsi, A.F. Scinto, Alice Villa, Alain Gelibter, C. De Angelis, Marco Mazzotta, Gennaro Ciliberto, Claudio Zamagni, Giuseppe Sanguineti, Fiorentino Izzo, Elizabeth H. Baldini, Rossana Berardi, Grr Ricciardi, Maddalena Barba, Ornella Garrone, Ida Paris, Luisa Carbognin, A. Botticelli, Giuseppina Sarobba, Silverio Tomao, Antonio Astone, Lucia Mentuccia, P Del Medico, Lorusso, Daniele Santini, M. Della Giulia, Riccardo Samaritani, Francesco Giotta, Alessandra Cassano, Laura Iezzi, Maria Agnese Fabbri, R De Maria, Eriseld Krasniqi, Raffaele Giusti, Sini, Lorenzo Livi, Ernesto Rossi, Andrea Michelotti, Emilio Bria, A Di Leo, Luca Moscetti, Corrado Ficorella, Antonino Grassadonia, Roberta Sarmiento, Katia Cannita, Filippo Greco, Sandro Barni, Elena Fiorio, Teresa Gamucci, Magri, Antonio Russo, M. De Tursi, N. La Verde, Daniele Generali, Paolo Marchetti

Publikováno v: International Journal of Cancer

We analyzed data from 738 HER2‐positive metastatic breast cancer (mbc) patients treated with pertuzumab‐based regimens and/or T‐DM1 at 45 Italian centers. Outcomes were explored in relation to tumor subtype assessed by immunohistochemistry (IHC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c744e104d7bb709c3f49904f7a5d8b4
http://hdl.handle.net/11573/1307277

A combination of ifosfamide and mitoxantrone as salvage therapy in patients with advanced ovarian cancer

Autor: Paolo Marolla, Enzo Maria Ruggeri, Mario Nardi, Federico Calabresi, G. Atlante, A. Iacovelli, M. Della Giulia, Camillo F. Pollera

Publikováno v: Cancer Chemotherapy and Pharmacology. 38:298-301

Ifosfamide (IFX) and mitoxantrone (MXN) have been found to be effective against advanced epithelial ovarian cancer. The combination of these two agents has not yet been tested in this setting but seems to be rational, given the different action mecha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2de66ee0d69e6e90b824d75d58438544
https://doi.org/10.1007/s002800050486

Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-αl and interferon-α2a

Autor: Guido Rasi, M. Della Giulia, Patrizia Vici, Enrico Garaci, M. D'Aprile, L. Di Lauro, Cartesio Favalli, M. Lopez, E. Capomolla, S. Santini, Giovanni Bonsignore

Publikováno v: European Journal of Cancer. 31:2403-2405

A phase II study was performed to evaluate the clinical and immunological effects of a regimen of cisplatin (DDP) and etoposide (VP-16) combined with thymosin-alpha 1 (TA1) and low-dose interferon-alpha 2a (IFN) in the treatment of patients with adva

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f567c5a6a0bda8df05a32ab9d19e06bd
https://doi.org/10.1016/0959-8049(95)00477-7

Single-agent ifosfamide in the treatment of anthracycline-refractory adult sarcomas

Autor: M, Lopez, S, Carpano, A, Amodio, T, Gionfra, M, Della Giulia, P, Foggi, C, Manfredi, G, Del Monte

Publikováno v: La Clinica terapeutica. 149(5)

The objective of this trial was to assess the therapeutic activity and toxicity of ifosfamide (IFO) with mesna uroprotection as salvage therapy in patients (pts) with soft tissue sarcomas (STS) who had failed high-dose epirubicin treatment.IFO was ad

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4ab56ea381982b3502445df5a3eca196
https://pubmed.ncbi.nlm.nih.gov/10052244

Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer: a phase II trial

Autor: L, Crinò, A M, Mosconi, G V, Scagliotti, G, Selvaggi, M, Rinaldi, M, Della Giulia, C, Gridelli, C, Calandri, F, De Marinis, M, Noseda, M, Tonato

We investigated the activity and toxicity of gemcitabine as a single agent in patients with advanced non-small cell lung cancer (NSCLC) after recurrence or failure of previous treatment with a platinum-containing regimen. From November 1995 to Octobe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::41cb45a86c752613c535d0d0f678a002
http://hdl.handle.net/2318/1691352